BUENA, N.J., March 12, 2018 -- Teligent, Inc. (NASDAQ:TLGT), a New Jersey-based specialty generic pharmaceutical company, announced the Company will hold a conference call at 4:30pm ET on Thursday March 15, 2018 to discuss the 4th quarter 2017 financial results and business update.
The Company invites you to listen to the call by dialing (866) 393-8366. International participants should call (409) 350-3154. Participants should ask to be joined into the Teligent, Inc. call.
This call is being webcast and can be accessed in the Investor Relations Section of Teligent, Inc.'s website at www.teligent.com.
About Teligent, Inc.
Teligent is a specialty generic pharmaceutical company. Our mission is to be a leading player in the specialty generic prescription drug market. Learn more on our website www.teligent.com.
Contact:
Damian Finio
Teligent, Inc.
(856) 336-9117
www.teligent.com


SpaceX Targets Starship Flight 14 With First V3 Starlink Satellite Launch
DBS Raises 2025 Outlook After Record Q2 Profit Driven by Wealth Management
Daimler Truck Q2 Profit Falls 18%, 2026 Outlook Raised
Cloudflare Stock Jumps 15% as Earnings Beat Estimates, 2026 Outlook Raised
Siemens Energy Q3 Profit Beats Forecast as AI-Driven Power Demand Fuels Growth
Heineken H1 Operating Profit Meets Forecast as Beer Volumes Beat Expectations
UOB Q2 Net Profit Rises 10% as Wealth Management Growth Boosts Earnings
Airbnb Stock Jumps After Q2 Earnings Beat, Strong 2026 Outlook
SK Hynix, Samsung Lead Asian Chip Stock Selloff After Sandisk, Western Digital Outlook
Glencore Posts Strong H1 2026 Earnings, Announces ASX Secondary Listing
Meta Ordered to Pay $567M Over Child Safety Violations in New Mexico
DeepSeek to Raise AI API Prices as Demand for New Models Surges
AMP Shares Surge 13% After Strong Profit and A$150 Million Buyback
UK AI Security Tests Reveal Anthropic and OpenAI Agents Attempted Unauthorized Actions
Sinopec Boosts Russian ESPO Oil Purchases as Middle East Supply Tightens
SanDisk Q4 Earnings Beat Estimates as Q1 Revenue Outlook Meets Expectations 



